microRNAs: new prognostic, diagnostic, and therapeutic biomarkers in cervical cancer

JS Nahand, S Taghizadeh‐boroujeni… - Journal of cellular …, 2019 - Wiley Online Library
Cervical cancer is as a kind of cancer beginning from the cervix. Given that cervical cancer
could be observed in women who infected with papillomavirus, regular oral contraceptives …

Current landscape of therapeutic resistance in lung cancer and promising strategies to overcome resistance

A Ashrafi, Z Akter, P Modareszadeh, P Modareszadeh… - Cancers, 2022 - mdpi.com
Simple Summary Despite an initial response to therapy, many lung cancer patients
inevitably develop resistance to therapy leading to decreased duration of response and …

Cancer stem cells in drug resistant lung cancer: Targeting cell surface markers and signaling pathways

G Leon, L MacDonagh, SP Finn, S Cuffe… - Pharmacology & …, 2016 - Elsevier
Lung cancer is the leading cause of cancer mortality worldwide. Despite advances in anti-
cancer therapies such as chemotherapy, radiotherapy and targeted therapies, five-year …

[HTML][HTML] Role of microRNAs in chemoresistance

P Magee, L Shi, M Garofalo - Annals of translational medicine, 2015 - ncbi.nlm.nih.gov
Drug resistance is a major problem in the treatment of cancer patients. Resistance can
develop after prolonged cycles of chemotherapy or can be present intrinsically in the patient …

Effects of propofol on cancer development and chemotherapy: Potential mechanisms

S Jiang, YA Liu, L Huang, F Zhang, R Kang - European Journal of …, 2018 - Elsevier
Abstract Propofol (2, 6-diisopropylphenol) is the commonly used intravenous sedative-
hypnotic agent. Accumulating evidence shows that propofol affects cancer development by …

A two-miRNA signature (miR-33a-5p and miR-128-3p) in whole blood as potential biomarker for early diagnosis of lung cancer

J Pan, C Zhou, X Zhao, J He, H Tian, W Shen, Y Han… - Scientific reports, 2018 - nature.com
MicroRNAs (MiRNAs) have been found to be dysregulated in lung cancer tissues compared
to their matched paracancerous tissues. However, the roles of miRNAs in peripheral blood …

Major tumor suppressor and oncogenic non-coding RNAs: clinical relevance in lung cancer

K Inamura - Cells, 2017 - mdpi.com
Lung cancer is the leading cause of cancer deaths worldwide, yet there remains a lack of
specific and sensitive tools for early diagnosis and targeted therapies. High-throughput …

N6-methyladenosine mediates the cellular proliferation and apoptosis via microRNAs in arsenite-transformed cells

S Gu, D Sun, H Dai, Z Zhang - Toxicology letters, 2018 - Elsevier
Abstract N 6-methyladenosine (m 6 A) modification is implicated to play an important role in
cellular biological processes, but its regulatory mechanisms in arsenite-induced …

Circulating exosomal miR‐96 as a novel biomarker for radioresistant non‐small‐cell lung cancer

Q Zheng, H Ding, L Wang, Y Yan, Y Wan… - Journal of …, 2021 - Wiley Online Library
Patients with non‐small‐cell lung cancer (NSCLC) frequently develop radioresistance,
resulting in poor response to radiation and unfavourable prognosis. Early detection of …

[HTML][HTML] MALAT1-miR-101-SOX9 feedback loop modulates the chemo-resistance of lung cancer cell to DDP via Wnt signaling pathway

W Chen, W Zhao, L Zhang, L Wang, J Wang, Z Wan… - Oncotarget, 2017 - ncbi.nlm.nih.gov
Cisplatin (DDP)-based chemotherapy is a standard strategy for lung cancer, while
chemoresistance remains a major therapeutic challenge. Recent evidence highlights the …